Zhao Yan New Medicine (06127.HK) plans to invest no more than 10 million yuan to participate in the establishment of a biopharmaceutical fund.

Zhaoyan Pharmaceuticals (06127.HK) announced that in order to fully leverage the advantages of professional investment institutions in resources, professional judgment, and investment management, the company or its designated subsidiaries plan to sign a "Partnership Agreement" with Yifeng Investment Management Enterprise (Limited Partnership) (hereinafter referred to as "Yifeng Capital"), Yifeng Mingyuan Technology Co., Ltd. (hereinafter referred to as "Yifeng Mingyuan"), and other related parties to initiate the establishment of Shenzhen Yifeng Guangming Science City Seed Fund (Limited Partnership) (hereinafter referred to as "this fund" or "partnership enterprise"). The partnership enterprise will focus on developing strategic emerging industries supported and encouraged by the Shenzhen government, future industries, and other industries of key development by the municipal government, with a particular emphasis on investment in the biopharmaceutical and high-end medical device sectors. The company or its designated subsidiary as a limited partner shall contribute a paid-in capital of no more than 10 million RMB.